Christopher W Kahler1, Nichea S Spillane2, Anne M Day2, Patricia A Cioe2, Acacia Parks3, Adam M Leventhal4, Richard A Brown5. 1. Center for Alcohol and Addiction Studies and the Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI; christopher_kahler@brown.edu. 2. Center for Alcohol and Addiction Studies and the Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI; 3. Department of Psychology, Hiram College, Hiram, OH; 4. Departments of Preventive Medicine and Psychology, University of Southern California Keck School of Medicine, Los Angeles, CA; 5. School of Nursing, University of Texas at Austin, Austin, TX.
Abstract
OBJECTIVE:Greater depressive symptoms and low positive affect (PA) are associated with poor smoking cessation outcomes. Smoking cessation approaches that incorporate a focus on PA may benefit smokers trying to quit. The purpose of this study was to conduct a pilot randomized clinical trial to compare standard smoking cessation treatment (ST) with smoking cessation treatment that targets positive affect, termed positive psychotherapy for smoking cessation (PPT-S). METHOD:Smokers who were seeking smoking cessation treatment were assigned by urn randomization to receive, along with 8 weeks of nicotine replacement therapy, either ST (n = 31) or PPT-S (n = 35). Seven-day point prevalence smoking abstinence was biochemically confirmed at 8, 16, and 26 weeks. RESULTS: Compared to ST, a greater percentage of participants in PPT-S were abstinent at 8 weeks, 16 weeks, and 26 weeks, but these differences were nonsignificant. In a more statistically powerful longitudinal model, participants in PPT-S had a significantly higher odds of abstinence (adjusted odds ratio [AOR] = 2.75; 95% CI = 1.02, 7.42; p = .046) across follow-ups compared to those in ST. The positive effect of PPT-S was stronger for those higher in PA (OR = 6.69, 95% CI = 1.16, 38.47, p = .03). Greater use of PPT-S strategies during the initial 8 weeks of quitting was associated with a less steep decline in smoking abstinence rates over time (OR = 2.64, 95% CI = 1.06, 6.56, p =.04). CONCLUSION: This trial suggests substantial promise for incorporating PPT into smoking cessation treatment.
RCT Entities:
OBJECTIVE: Greater depressive symptoms and low positive affect (PA) are associated with poor smoking cessation outcomes. Smoking cessation approaches that incorporate a focus on PA may benefit smokers trying to quit. The purpose of this study was to conduct a pilot randomized clinical trial to compare standard smoking cessation treatment (ST) with smoking cessation treatment that targets positive affect, termed positive psychotherapy for smoking cessation (PPT-S). METHOD: Smokers who were seeking smoking cessation treatment were assigned by urn randomization to receive, along with 8 weeks of nicotine replacement therapy, either ST (n = 31) or PPT-S (n = 35). Seven-day point prevalence smoking abstinence was biochemically confirmed at 8, 16, and 26 weeks. RESULTS: Compared to ST, a greater percentage of participants in PPT-S were abstinent at 8 weeks, 16 weeks, and 26 weeks, but these differences were nonsignificant. In a more statistically powerful longitudinal model, participants in PPT-S had a significantly higher odds of abstinence (adjusted odds ratio [AOR] = 2.75; 95% CI = 1.02, 7.42; p = .046) across follow-ups compared to those in ST. The positive effect of PPT-S was stronger for those higher in PA (OR = 6.69, 95% CI = 1.16, 38.47, p = .03). Greater use of PPT-S strategies during the initial 8 weeks of quitting was associated with a less steep decline in smoking abstinence rates over time (OR = 2.64, 95% CI = 1.06, 6.56, p =.04). CONCLUSION: This trial suggests substantial promise for incorporating PPT into smoking cessation treatment.
Authors: Ellen S Burgess; Richard A Brown; Christopher W Kahler; Raymond Niaura; David B Abrams; Michael G Goldstein; Ivan W Miller Journal: J Consult Clin Psychol Date: 2002-04
Authors: David R Strong; Christopher W Kahler; Adam M Leventhal; Ana M Abrantes; Elizabeth Lloyd-Richardson; Raymond Niaura; Richard A Brown Journal: Nicotine Tob Res Date: 2009-07-02 Impact factor: 4.244
Authors: Bryan W Heckman; K Michael Cummings; Jonathan J K Stoltman; Jennifer Dahne; Ron Borland; Geoffrey T Fong; Matthew J Carpenter Journal: Behav Res Ther Date: 2018-11-23
Authors: Laura D Kubzansky; Jeff C Huffman; Julia K Boehm; Rosalba Hernandez; Eric S Kim; Hayami K Koga; Emily H Feig; Donald M Lloyd-Jones; Martin E P Seligman; Darwin R Labarthe Journal: J Am Coll Cardiol Date: 2018-09-18 Impact factor: 24.094
Authors: Christopher W Kahler; Anthony Surace; Rebecca E F Gordon; Patricia A Cioe; Nichea S Spillane; Acacia Parks; Beth C Bock; Richard A Brown Journal: Contemp Clin Trials Date: 2018-06-21 Impact factor: 2.226